SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A quarterly earnings beat, rapid growth in AI-compute revenue and an aggressive expansion outlook are driving attention, alongside preliminary discussions of a possible Tesla merger. Many traders are bullish on the growth story and anticipate further gains, while skeptics question the valuation, heavy spending and credibility of Musks ambitious forecasts.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary update sharply raised its quarterly revenue and gross-margin outlook on stronger AI platform demand, driving a strong after-hours rally. Traders largely welcomed the results as evidence of improving business momentum and a possible short squeeze, while some questioned whether the gains would hold given the companys history of volatility and execution concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth, and a reduced advertising outlook, prompting a sharp selloff. Traders are split between viewing the decline as an overreaction and expecting further downside amid concerns about growth and competition.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is drawing attention after beating quarterly expectations and raising its outlook, yet its shares fell as traders focused on weaker cash flow, rising costs, and a loss in its insurance business. The reaction has frustrated bullish holders, while others see the selloff as evidence that strong results were already priced in.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELHs move toward and briefly above the $30 level has traders focused on whether the stock can sustain a technical breakout, with some pointing to higher volume and others expecting another rejection. Pepsi buyout talk and hopes around earnings appear in the discussion, but remain speculation rather than a confirmed catalyst.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals Q3 results beat expectations, but shares sold off sharply as traders focused on slower U.S. procedure growth, planned da Vinci pricing cuts, and a one-time antitrust settlement. The community is split between calling the decline an overreaction to solid business growth and seeing the guidance and pricing pressures as reasons for caution.

TOSHI

TOSHI is drawing attention amid a rebound and traders repeated focus on breaking a stubborn resistance level, with technical breakout and short-squeeze hopes driving bullish posts. Others remain cautious, pointing to repeated rejections, weak price action, and sensitivity to Bitcoins direction; talk of a coming announcement or listing remains speculative.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicines shares are drawing attention after bitopertins Phase 3 APOLLO trial met its endpoints and the company priced an upsized public offering. Traders are weighing the stronger regulatory prospects against dilution and potential selling pressure from the financing.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is in focus ahead of its quarterly earnings report, with traders watching guidance and semiconductor-equipment demand amid a sharp pullback. The debate is split between buyers treating weakness and support levels as an opportunity and bears concerned about further sector pressure and high expectations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the Phase 3 REGAL AML trial reaching its 80-event final-analysis trigger; the last disclosed count was 78, and traders are also watching for SLS009 updates. Some interpret the CEOs next chapter remarks and the companys ASH presence as possible buyout or partnership clues, while skeptics note there is no confirmed deal or trial result and view the rally as speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced it will present two presentations at the upcoming ObesityWeek 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C. The first late-breaking oral presentation will feature topline results from...

Amylyx Pharma Q2 2026 Earnings Call Transcript

Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This transcript is brought to you by Benzinga APIs. For real-time access to ourread more...

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET. A live webcast of the presentation can be...

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15th, 2026, at 12:20 p.m. ET. A live webcast of the presentation...

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Key PointsAnalysts also raised their price targets on the company...

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? 

Equity

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence. 


Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to...

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus

The U.S. 30-year Treasury yield climbed to a fresh 19-year high on Tuesday, trading at 5.274% at the time of writing, while the 10-year Treasury yield was at 4.692%.

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? 

Investors responded to clinical progress, improving commercial performance and new growth opportunities.


Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Iovance Biotherapeutics hit a 52-week high as UBS lifted its price target.&nbsp;</li><li>Amylyx Pharmaceuticals hit a three-year high after pricing a $500 million stock offering to fund potential commercialization.&nbsp;</li><li>Morgan Stanley raised ConocoPhillips’ price target to $151 with an ‘Overweight’ rating.</li></ul>Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX) and ConocoPhillips (COP) stocks each reached fresh 52-week highs on Thursday as operating milestones and favorable analyst calls improved investor confidence.&nbsp;Iovance Biotherapeutics stock surged 12%, while Amylyx Pharmaceuticals and ConocoPhillips stocks gained over 2% and 3%, respectively.&nbsp;<h2 class="st-heading-2">UBS Raises Iovance Price Target&nbsp;</h2><a href="https://stocktwits.com/symbol/IOVA">Iovance Biotherapeutics stock</a> hit an annual high of $9.36 as strong second-quarter performance and bullish analyst updates fueled its recent rally. The company reported $99.3 million in fiscal second-quarter (Q2) product revenue, including $91 million in U.S. Amtagvi sales, up 52% from the previous quarter. Gross margin also improved to 56%, helped by better manufacturing efficiency and faster treatment turnaround times.&nbsp;Wall Street analysts added to the positive sentiment. On Thursday, UBS raised its price target to $7 while maintaining a ‘Neutral’ rating, citing better performance at treatment centers and improved manufacturing. Iovance expects to have 110 active authorized treatment centers by year-end, while investors are also watching for SARATOGA trial results expected in late October.On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">$500M Offering Adds Firepower To Amylyx’s Growth Plans&nbsp;</h2><a href="https://stocktwits.com/symbol/AMLX">Amylyx Pharmaceuticals stock</a> surged to a three-year high of $40.44 on continued momentum of strong Phase 3 results for its experimental drug avexitide and a major new capital raise.&nbsp;On Tuesday, the company said its LUCIDITY Phase 3 trial met its main goal in treating post-bariatric hypoglycemia (PBH). Avexitide reduced the combined rate of severe hypoglycemic events by 55% versus placebo and met secondary goals. Amylyx plans to submit the drug for FDA approval by the end of 2026. Riding the positive clinical news, Amylyx priced an upsized $500 million stock offering at $35.50 per share. The financing gives the company capital to prepare for a potential commercial launch while reducing its reliance on debt.&nbsp;Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Morgan Stanley Sees More Upside For ConocoPhillips&nbsp;</h2><a href="https://stocktwits.com/symbol/COP">ConocoPhillips stock</a> hit a three-year high of $135.87 as investors continued to respond to strong second-quarter results, higher production and positive analyst calls. Earlier this month, the oil and gas company reported adjusted earnings of $3.24 per share, beating Wall Street's $2.85 estimate. Production also reached 2.248 million barrels of oil equivalent per day, exceeding the top end of its guidance.&nbsp;Morgan Stanley raised its price target to $151 with an ‘Overweight’ rating, implying a 12% upside to the stock’s last close. Analyst Devin McDermott noted that, unlike pure-play refiners, integrated energy companies have not benefited as much from stronger refining margins, leaving room for their shares to catch up.Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;So far this year, COP, AMLX and IOVA stocks have surged between 44% and 229%Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wmt-vs-tgt-walmart-has-the-scale-target-has-turnaround-momentum-which-retail-stock-looks-better-now/cZYBiRVRJZC">WMT Vs TGT: Walmart Has The Scale, Target Has Turnaround Momentum — Which Retail Stock Looks Better Now?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?

Conoco Phillips

Iovance Biotherapeutics Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.77
Prev Close	$27.33
Open	$27.54
Dividend Yield	0.00%
50-Day Moving Average	$30.90
Beta	1.76
Avg. Volume	1.49M
PE Ratio	-20.08

52-Week High	$41.14
52-Week Low	$10.83
Market Capitalization	$3.43B
EPS (Annual)	-$1.53
Price to Book	13.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMLX Fundamentals